Nuvectis Pharma (NVCT) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free NVCT Stock Alerts $6.51 -0.20 (-2.98%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIs Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - April 17 at 10:02 AMNuvectis Pharma, Inc. to Post Q1 2024 Earnings of ($0.39) Per Share, HC Wainwright Forecasts (NASDAQ:NVCT)marketbeat.com - April 11 at 7:26 AMAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)markets.businessinsider.com - April 8 at 6:43 PMNuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Linesfinanznachrichten.de - April 8 at 1:42 PMNuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick Factsmarkets.businessinsider.com - April 8 at 1:42 PMNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Linesfinance.yahoo.com - April 8 at 8:41 AMNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Linesglobenewswire.com - April 8 at 8:30 AM5 Healthcare Stocks to Buy for 2024investorplace.com - April 2 at 4:30 PMInsider Buys Additional US$51k In Nuvectis Pharma Stockfinance.yahoo.com - March 21 at 6:37 AMInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases 5,000 Shares of Stockinsidertrades.com - March 20 at 7:19 AMNuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases $51,450.00 in Stockmarketbeat.com - March 19 at 10:28 AMNuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meetingglobenewswire.com - March 19 at 8:00 AMNuvectis reports initial data from Phase Ib ovarian cancer trialmsn.com - March 15 at 9:38 PMNuvectis Pharma Shares Rise 11% After Positive Preliminary Data for Cancer Treatmentmarketwatch.com - March 15 at 9:48 AMNuvectis Pharma to Present at the 36th Annual Roth Conferenceglobenewswire.com - March 15 at 8:00 AMmarketbeat.com - March 14 at 9:41 AMNuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancerglobenewswire.com - March 14 at 9:00 AMFY2027 EPS Estimates for Nuvectis Pharma, Inc. Decreased by Analyst (NASDAQ:NVCT)marketbeat.com - March 6 at 8:33 AMNVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023investorplace.com - March 6 at 1:36 AMNuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progressfinance.yahoo.com - March 5 at 10:11 AMNuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownershipfinance.yahoo.com - February 19 at 12:09 PMNuvectis Pharma Inc NVCTmorningstar.com - February 9 at 11:49 PMCorrection: Nuvectis Pharma Announces Participation at Upcoming Investor Conferencesfinance.yahoo.com - February 9 at 8:47 AMNuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 12:55 PMNuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinomafinance.yahoo.com - December 18 at 8:13 AMNuvectis Pharma Insiders Added US$3.75m Of Stock To Their Holdingsfinance.yahoo.com - November 25 at 11:11 AMNuvectis Pharma GAAP EPS of -$0.37msn.com - November 8 at 2:06 PMRecap: Nuvectis Pharma Q3 Earningsbenzinga.com - November 8 at 9:05 AMNuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancerfinance.yahoo.com - October 24 at 9:47 AMWe Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefullyfinance.yahoo.com - October 16 at 3:53 PMDown -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)msn.com - October 16 at 10:53 AMNuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentationfinance.yahoo.com - September 25 at 11:00 PMBaldwin Brothers LLC MA Sells 53,739 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT)marketbeat.com - September 22 at 9:37 AMNuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900finance.yahoo.com - September 21 at 12:45 PMHC Wainwright & Co. Reiterates Nuvectis Pharma (NVCT) Buy Recommendationmsn.com - September 16 at 4:54 AMNuvectis Pharma (NASDAQ:NVCT) Rating Reiterated by HC Wainwrightmarketbeat.com - September 15 at 1:29 PMNuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Significant Drop in Short Interestmarketbeat.com - September 15 at 8:26 AMAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Werewolf Therapeutics (HOWL)markets.businessinsider.com - September 15 at 8:03 AMNuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trialfinance.yahoo.com - September 12 at 9:41 AMWith 67% ownership, insiders at Nuvectis Pharma, Inc. (NASDAQ:NVCT) are pretty optimistic and have been buying recentlyfinance.yahoo.com - September 12 at 9:41 AMNuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900finance.yahoo.com - September 6 at 10:08 AMNuvectis Pharma Announces Participation at Upcoming Investor Conferencesfinance.yahoo.com - September 1 at 1:57 PM24,570 Shares in Nuvectis Pharma, Inc. (NASDAQ:NVCT) Bought by Edmond DE Rothschild Holding S.A.marketbeat.com - August 25 at 8:59 AMNuvectis Pharma Says FDA Grants Orphan Drug Designation To NXP800 For Cholangiocarcinomamarkets.businessinsider.com - August 17 at 9:33 AMNuvectis Gets FDA Orphan Designation for NXP800 in Cholangiocarcinoma >NVCTmarketwatch.com - August 17 at 9:33 AMNuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinomafinance.yahoo.com - August 17 at 9:33 AM10% Owner of Nuvectis Pharma Purchased $119K In Stockbenzinga.com - July 25 at 11:21 PMNuvectis Pharma 10% Owner Trades Company's Stockbenzinga.com - July 19 at 1:24 PM10% Owner of Nuvectis Pharma Makes $153K Buybenzinga.com - July 12 at 3:03 PM10% Owner At This Health Care Company Buys $135K of Stockbenzinga.com - July 11 at 1:36 PM Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). NVCT Media Mentions By Week NVCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCT News Sentiment▼0.000.41▲Average Medical News Sentiment NVCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCT Articles This Week▼01▲NVCT Articles Average Week Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RPTX News OPTN News VTGN News CTMX News ELYM News KPTI News FGEN News CTXR News COYA News SCTL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
